Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a blank check company incorporated as a special purpose acquisition company with a focus on the healthcare and biopharmaceutical sector, particularly immunotherapy. The company filed its 10-Q quarterly report on August 8, 2022, reflecting its continued search for a business combination target within the life sciences industry. ESLA completed its IPO in 2021 and was searching for a merger partner in the biotechnology and pharmaceutical space at the time of filing. The filing, carrying accession number 0001410578-22-002124, provides an update on the company's operational status as a pre-combination SPAC. Sign up for a full SpacDesk account to access complete filing history, deal timelines, and real-time data on ESLA and hundreds of other active and historical SPACs.